使用Vericiguat治疗的患者中利钠肽水平和心脏结构的变化

Limitations

• Survival bias, as only patients who survived for at least 6 months and had available echocardiogram data were enrolled
• Lack of a control group not treated with vericiguat
• Potential underreporting or misclassification of events due to retrospective data collection from electronic medical records
• Effects of subsequent treatments or medications initiated after baseline were not assessed
• Limited generalizability to other countries as the study was conducted exclusively in Japan